Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered immune cells offer new hope for tough leukemia

NCT ID NCT03919240

First seen Apr 23, 2026 · Last updated May 24, 2026 · Updated 6 times

Summary

This study tests a personalized cell therapy for people with B-cell acute lymphoblastic leukemia that has not responded to standard treatments. The therapy uses the patient's own immune cells, modified to target and destroy cancer cells. The goal is to achieve remission and monitor long-term survival and relapse rates.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA WITH FAILED REMISSION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Fisrt Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, 215006, China

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.